Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?

Ozkan, MetinBozkurt, OktayHacibekiroglu, IlhanKaplan, Muhammet AliDuzkopru, YakupUysal, MukreminKaraca, Halit2024-04-242024-04-2420150732-183X1527-7755https://doi.org/10.1200/jco.2015.33.15_suppl.e15624https://hdl.handle.net/11468/18295Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer -- MAY 29-JUN 02, 2015 -- Chicago, IL[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keyword]Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?Conference Object3315WOS:00035803690316310.1200/jco.2015.33.15_suppl.e15624Q1